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A B S T R A C T
Objective: To investigate the association between nonalcoholic fatty liver disease (NAFLD) 
and metabolic syndrome (MS) in the preoperative period in patients undergoing bariatric 
surgery. 
Methods: A total of 68 medical records of patients from a center for advanced treatment of 
obesity in the city of Caxias do Sul, state of Rio Grande do Sul, Brazil, were reviewed. The 
variables analyzed were gender, age, biochemical parameters (fasting glucose, HDL-choleste-
rol and triglycerides), abdominal ultrasound, blood pressure, and anthropometric data 
(weight, height, waist circumference, and body mass index [BMI]). The diagnosis of NAFLD was 
obtained by abdominal ultrasonography; the diagnosis of of MS was obtained according to the 
protocol described by the National Cholesterol Education Program’s Adult Treatment Panel III, 
updated by the American Heart Association; and the National Heart, Lung, and Blood Institute. 
Results: 72.1% (n  =  49) of the sample consisted of females, and the mean age for the 
sample was 37.57 ± 10.29 years. The mean weight was 123.14 ± 25.40 kg, mean height was 
1.67 ± 0.09 m, and mean BMI was 56.24 ± 9.30 kg/ m². A total of 60% (n = 27) of patients with 
MS (p = 0.008), 63.4% (n = 26) of patients with hypertension (p = 0.013), and 66.7% (n = 18) of 
patients with altered glucose levels (p = 0.028) were diagnosed with NAFLD.
Conclusion: The results of this study showed that the diagnosis of MS, as well as the presence 
of disorders associated with this syndrome (obesity, hypertension, and high blood glucose 
levels) are strongly associated with the presence of NAFLD. 
Doença hepática gordurosa não alcoólica e sua relação com a síndrome 
metabólica no pré-operatório de pacientes submetidos à cirurgia bariátrica
R E S U M O
Objetivo: Verificar a relação entre a doença hepática gordurosa não alcoólica (DHGNA) e 
síndrome metabólica (SM) no período pré-operatório de pacientes submetidos à cirurgia 
bariátrica.
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Obesidade
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Introduction
Considered a major public health problem, obesity has been 
increasing its prevalence at an alarming rate in recent years. 
Changes in the lifestyle and education of the population, which 
has become more sedentary and has acquired inadequate 
eating habits, have been identified as the main causes of this 
increase.1,2 In Brazil, according to the Household Budget Survey 
(HBS), conducted in 2008 and 2009, 50.1% of men and 48% of 
women are overweight.3 Another study performed by the 
Surveillance of Risk Factors and Protection for Chronic Diseases 
through Telephone Interviews (Vigilância de Fatores de Risco 
e Proteção para Doenças Crônicas por Inquérito Telefônico 
– VIGITEL) in 2011 showed that 15.8% of the Brazilian adult 
population is obese.4 Along with the increase in obesity, the 
prevalence of chronic diseases has also grown. Among them, 
nonalcoholic fatty liver disease (NAFLD)5,6 and the metabolic 
syndrome (MS) must be highlighted.7 
NAFLD is a condition defined by an abnormal clinico-
pathological accumulation of triglycerides in hepatocytes, 
exceeding 5% of the liver weight.8 It has different stages, 
ranging from simple accumulation (NAFLD) to accumulation 
with inflammation (non-alcoholic steatohepatitis [NASH]), and 
can progress to fibrosis, cirrhosis, or hepatocellular carcinoma.5
It is estimated that NAFLD affects 10% to 24% of the 
population in many countries worldwide. This prevalence 
grows alarmingly in the obese population, reaching 57.5% to 
74%.9 
NAFLD is strongly associated with insulin resistance, 
diabetes mellitus type II, obesity, and dyslipidemia.10 It is more 
common among men and its prevalence increases with age.11 
Its diagnosis requires the exclusion of alcoholic liver disease 
(ALD) and viral hepatitis,12 and can be attained by abdominal 
ultrasound, a noninvasive, inexpensive and easily accessible 
method that can detect NASH levels as mild, moderate, or 
severe, with a sensitivity of 60% to 94% and specificity of 88% 
to 95%.13-15 
MS is defined as a complex disorder represented by a set of 
cardiovascular risk factors that are typically associated with 
insulin resistance and central adiposity.7 Among the main 
factors contributing to its occurrence are genetic predisposition, 
inadequate diet, and physical inactivity.16,17 Although not part 
of the diagnostic criteria of MS, NAFLD is frequently associated 
with this disorder.7
Therapeutic treatment for NAFLD involves weight loss 
through dietary changes, associated or not to physical exercise, 
or bariatric surgery.6 Body weight reduction through bariatric 
surgery leads to an improvement in patients’ biochemical and 
histological profiles, as well as in steatosis and inflammation 
in patients with NAFLD.6 Thus, the present study aimed to 
investigate the relationship between NAFLD and metabolic 
syndrome in the preoperative period in patients undergoing 
bariatric surgery. 
Methods
This was a retrospective cross-sectional study that reviewed 
the medical records of patients from a center of advanced 
treatment of obesity in the city of Caxias do Sul, state of Rio 
Grande do Sul, Brazil. The study was approved by the Research 
Ethics Committee of Faculdade Nossa Senhora de Fátima.
The sample consisted of 199 medical records of obese 
patients who underwent bariatric surgery between 2008 and 
April, 2012. Of these, 68 records met the inclusion criteria, 
which were patients of both genders, aged ≥ 20 years, who had 
abdominal ultrasonography. All patients had a body mass index 
(BMI) ≥ 40 kg/m², or ≥ 35 kg/m² associated with one or more 
comorbidities (hypertension, dyslipidemia, or altered glucose 
levels). None of these patients had alcohol consumption > 20 g 
of ethanol per day or had a positive diagnosis of viral hepatitis. 
The studied variables were gender, age, biochemical 
parameters (fasting glucose, HDL-cholesterol, and triglycerides), 
abdominal ultrasound, blood pressure, and anthropometrics 
(weight, height, waist circumference, and BMI). 
Métodos: Foram revisados 68  prontuários de pacientes de um centro de tratamento 
avançado da obesidade da cidade de Caxias do Sul – RS. As variáveis estudadas foram 
gênero, idade, parâmetros bioquímicos (nível de glicose em jejum, colesterol HDL e 
triglicerídeos), ultrassonografia abdominal, pressão arterial e antropometria (peso, 
estatura, circunferência abdominal e índice de massa corporal [IMC]). O diagnóstico da 
DHGNA foi obtido pela ultrassonografia abdominal e o da SM através do protocolo descrito 
pelo National Cholesterol Education Program’s Adult Treatment Panel III, atualizado pela 
American Heart Association; e a National Heart, Lung, and Blood Institute.
Resultados: 72,1% (n  =  49) da amostra foi composta pelo gênero feminino e a média 
de idade encontrada na população foi de 37,57±10,29  anos. A média de peso entre eles 
foi de 123,14±25,40 kg, a altura de 1,67±0,09 m e o valor médio de IMC de 56,24±9,30 kg/
m2. Apresentaram diagnóstico de DHGNA 60% (n =  27) dos pacientes portadores de SM 
(p = 0,008), 63,4% (n = 26) dos pacientes portadores de hipertensão arterial (p = 0,013) e 66,7% 
(n = 18) dos pacientes que apresentaram níveis glicêmicos alterados (p = 0,028).
Conclusão: Os resultados do presente estudo mostraram que o diagnóstico de SM, bem como 
a presença das desordens associadas a esta (obesidade, hipertensão arterial e elevação nos 
níveis glicêmicos) estão fortemente relacionadas à presença da DHGNA.
Síndrome metabólica
Cirurgia bariátrica
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Grade II obesity was considered in patients with BMI 
35.0-39.9  kg/m², and grade III obesity in those with 
BMI ≥ 40.0 kg/m².18 NAFLD diagnosis was obtained through 
abdominal ultrasonography, which classifies NASH as 
mild (slight diffuse increase of fine echoes in the hepatic 
parenchyma, with normal visualization of the diaphragm 
and intrahepatic vessel walls), moderate (moderate diffuse 
increase of fine echoes with slight difficulty in visualization 
of the vascular wall and diaphragm), or severe (significant 
increase of fine echoes with poor visualization of the 
diaphragm, vascular walls, and posterior segments of the 
right lobe, which could increase liver volume).19 
The diagnosis of MS was attained using the protocol 
described by the National Cholesterol Education Program’s 
Adult Treatment Panel III (NCEP-ATP III, 2001), updated by 
the American Heart Association, and the National Heart, 
Lung, and Blood Institute (AHA / NHLBI, 2005), which 
considers that the patient has MS when three or more 
risk factors described below are associated: high waist 
circumference (≥ 102 cm for men and ≥ 88 cm for women), 
high triglycerides (≥  150  mg/dL or specific treatment), 
reduced HDL cholesterol (< 40 mg/dL for men and < 50 mg/
dL for women, or specific treatment), high blood pressure 
(≥ 130 / ≥ 85 mmHg, or drug treatment for hypertension), 
elevated fasting glucose (≥ 100 mg/dL, or recently diagnosed 
diabetes mellitus type II).20-22 
Data were entered in duplicate into a Microsoft 
Excel 2007® spreadsheet and were analyzed using Stata 
software, version 11.0. Analyses of data consistency were 
initially conducted, followed by descriptive analyses. 
The associations of the outcome “NAFLD” with the “MS” 
exposure and other explanatory variables were tested using 
the chi-squared test and linear association, and prevalence 
ratios with their respective 95% confidence intervals (95% 
CI) were calculated.
Results
The medical records of 68 patients were evaluated, of which 
72.1% (n = 49) were of female patients; the mean age of the 
sample was 37.57 ± 10.29 years. 
The  s tudy  populat ion  had  a  mean weight  o f 
123.14 ± 25.40 kg, mean height of 1.67 ± 0.09 m, and a mean 
BMI of 56.24 ± 9.30 kg/m². Considering the classification 
of BMI,18 35.3% (n = 24) patients were identified as having 
grade II obesity, and 64.7% (n = 44) as grade III obesity. 
NASH, diagnosed by abdominal ultrasonography, was 
present in 50% (n = 34) of patients; 20.3% (n = 14) presented 
mild NASH, 17.4% (n = 12), moderate, and 11.6% (n = 8) severe. 
The disease was more prevalent among male patients (52.6%), 
but no statistical significance was found between genders. 
Regarding age range, a linear trend was observed, where 
there was an increase in the prevalence of the outcome 
with increasing age, which was not statistically significant 
(p = 0.673), as shown in Figure 1.
MS was present in 66.2% (n = 45) of studied patients. 
Among the criteria for this diagnosis, 60.3% (n = 41) had 
hypertension, 39.7% (n = 27) had altered glucose levels, 100% 
(n = 68) had high waist circumference, 57.4% (n = 39) had 
hypertriglyceridemia, and 45.6% (n = 31) had reduced HDL 
cholesterol levels.
The population studied had mean glucose level of 
106.94  ±  32.84  mg/dL and mean waist circumference 
of 121.06  ±  16.67  cm. Mean triglyceride levels were 
196.09  ±  119.73  mg/dL, and mean HDL cholesterol was 
49.51 ± 11.92 mg/dL. Blood pressure classification followed 
the diagnosis of hypertension that was already established in 
the patients’ charts.
Table 1 shows that among the 41 (60.3%) patients with 
hypertension, 26 (63.4%) had a diagnosis of NASH, showing an 
increased risk for developing the disease in the presence of 
hypertension (p = 0.002).
The presence of altered glucose levels in patients also 
showed to be statistically associated with increased prevalence 
of NASH (p = 0.015). For this variable, it was found that among 
the 27 (39.7%) patients with altered glucose levels, 18 (66.7%) 
had a diagnosis of NASH. 
The study demonstrated that among the 39 (57.4%) patients 
with hypertriglyceridemia, 20 (51.3%) had a diagnosis of NASH. 
A statistically significant result was not observed between 
the variable and the outcome (p = 0.598), but it showed that 
patients with hypertriglyceridemia have an 8% higher risk of 
developing the outcome when compared to those who do not 
have this alteration.
Patients that had inadequate levels of HDL-cholesterol had 
a higher prevalence of NASH (58.1%) when compared with 
patients with adequate HDL levels (40.5%). The difference 
between the prevalences showed no statistical significance 
(p = 0.150), but showed that patients who have adequate 
levels of HDL cholesterol are 72% less likely to develop the 
outcome, as compared to those who have inadequate HDL 
levels. 
When analyzing the variable of greatest interest for this 
study, it was found that the presence of MS was statistically 
associated with the development of NASH (p = 0.008). It 
was observed that among the 66.2% (n = 45) patients with 
MS, 60% (n = 27) were diagnosed with NASH by abdominal 
ultrasonography. When separated into the NASH classification 
of mild, moderate, and severe, it was found that 100% of 
patients diagnosed with moderate NASH, 83.3% of patients 
with severe NASH, and 61.54% of patients with mild NASH 
were diagnosed with MS.
70
60
50
40
30
20
10
0
 20 to 29 years 30 to 39 years 44 to 49 years ≥ 50 years
33.3%
48.1% 50%
66.7%
Fig. 1 − Prevalence of nonalcoholic fatty liver disease 
in obese patients submitted to bariatric surgery by age 
(p = 0.673).
158 REV ASSOC MED BRAS. 2013;59(2):155-160
Discussion
Obesity has become a major public health problem in both 
developed and developing countries.1 Currently, studies show 
that obesity has been identified as a significant risk factor for 
the increase in non-transmissible chronic diseases, among 
them, NAFLD and MS.5-7 
It is estimated that NAFLD affects 57.5% to 74% of the 
obese population in several countries worldwide,9 and this 
prevalence has alarmingly increased in patients undergoing 
bariatric surgery, ranging from 84% to 96%.23 Unlike what has 
been suggested by Clark et al.,23 the present study showed 
that 50% of patients undergoing bariatric surgery have NAFLD. 
The findings regarding age and gender of the study 
population are very close to those found in a study conducted 
in Brazil involving 1,280 patients, in which the mean age of 
patients with NAFLD was 49.8 (± 13.59) years and of which 
53.3% were males.11 
Regarding the diagnosis of NAFLD, a liver biopsy is still 
considered the gold standard, but it is a costly, invasive 
method associated with a low, but significant risk for patients 
who undergo this procedure.24 For this reason, the use of an 
imaging test such as abdominal ultrasonography to screen for 
NAFLD is a good method, as it has low cost when compared to 
others, is noninvasive, and is available in almost all centers. 
The abdominal ultrasound, a method used in this study, is used 
to detect NASH levels as mild, moderate, or severe, having good 
sensitivity and specificity.13-15 It is noteworthy that no imaging 
test can distinguish NASH from NAFLD, or define the severity 
of liver disorders. The method that can make this distinction, 
and also assess the degree of fibrosis, excluding other causes of 
liver disease and determining disease prognosis is liver biopsy, 
but for the reasons already mentioned, in clinical practice this 
procedure is only indicated for patients with higher likelihood 
of liver fibrosis.25,26 
Although it is not part of the diagnostic criteria, NAFLD is 
often associated with MS.7 Authors have shown that over 90% 
of patients with NAFLD had at least one of the parameters 
related to the diagnosis of MS, and approximately 33% had 
the syndrome.27 A study of 69 patients aiming to describe 
this association demonstrated an even higher prevalence, 
concluding that MS was three times more common in the group 
who had NAFLD diagnosed by abdominal ultrasonography 
than the group with no evidence of NAFLD.28 This is in 
accordance with the results found in the present study, which 
demonstrated that 60% of patients with MS have NAFLD. These 
findings suggest that NAFLD can be described as the liver 
manifestation of metabolic syndrome.27,29 
Diabetes mellitus affects approximately 12 million people 
in Brazil.30 NAFLD has been strongly associated with patients 
that have increased glucose levels, with a prevalence of 
Frequency Prevalence PR
 n (%) Steatosis p-value (CI)
Gender* 0.673
 Female 49 (72.1) 46.9 1
 Male 19 (27.9) 52.9 1.09 (0.62-1.92)
Age range* 0.395
 20-29  15 (22.1) 33.3 1
 30-39 27 (39.7) 48.1 1.43 (0.56-3.64)
 40-49 14 (20.6) 50.0 1.62 (0.61-4.31)
 ≥ 50 years 12 (17.6) 66.7 2.16 (0.86-5.41)
BMI* 0.858
 Grade II obesity 24 (35.3) 50.0
 Grade III obesity 44 (64.7) 47.7
Arterial hypertension* 0.002
 Yes 41 (60.3) 63.4 1
 No 27 (39.7) 25.9 0.41 (0.20-0.83)
Altered glycemia* 0.015
 Yes 27 (39.7) 66.7 1
 No 41 (60.9) 36.6 0.56 (0.33-0.93)
Hypertriglyceridemia* 0.598
 Yes 39 (57.4) 51.3 1
 No 29 (42.6) 44.8 0.92 (0.45-1.57) 
HDL cholesterol classification* 0.150
 Adequate 37 (54.4) 40.5 1
 Inadequate 31 (45.6) 58.1 1.28 (0.76-2.16)
Metabolic syndrome* 0.008
 Yes 45 (66.2) 60.0 1
 No 23 (33.8) 26.1  0.44 (0.21-0.93)
CI, confidence interval; BMI, body mass index; HDL, high density lipoprotein. 
*p-value per Pearson’s chi-square test.
Table 1 − Sample distribution according to patients’ demographic and health variables and prevalence of hepatic 
steatosis in patients undergoing bariatric surgery performed in Caxias do Sul, Rio Grande do Sul, Brazil, 2012 (n = 68).
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62%.31 In the present study, the prevalence was 66.7%, which 
is very similar to the aforementioned. A study of 100 patients 
with diabetes mellitus type II showed a 49% incidence of 
NAFLD,32 while a second study diagnosed NAFLD in 42% of 
such patients,33 confirming that the increase in blood glucose 
is a strong risk factor for NAFLD.
Arterial hypertension has also been shown to be a common 
finding in patients with NAFLD.34 Cotrim et al.11 reported that 
64% of patients with NAFLD were hypertensive, a prevalence 
that is consistent with that found in this study.
Dyslipidemia is a disorder that is often associated with the 
diagnosis of NASH.10 A study of 304 patients with a NAFLD 
diagnosis reported that 64% had hypertriglyceridemia, and 30% 
to 42% of cases had decreased HDL-cholesterol levels.27 These 
results differ from those found in the present study, which 
showed a lower prevalence of hypertriglyceridemia and a 
higher prevalence of altered levels of HDL cholesterol. These 
differences in results may have been due to the fact that the 
sample population of this study consisted of an insufficient 
number of patients.
Conclusion
The present study showed that both the presence of MS 
and the disorders associated with it (obesity, hypertension, 
and high blood glucose levels) are strongly associated with 
the presence of NAFLD. Results suggest that NAFLD can be 
considered the hepatic manifestation of MS. 
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